Xintian Pharma(SZ:002873)2025-08-26 10:38R&D Pipeline and Innovations - The company has three ongoing 1.1 class clinical phase III projects and has made breakthroughs in other important therapeutic areas, including oncology, cardiovascular, gynecology, and urology [2][3]. - In the oncology field, a modified new drug for auxiliary treatment has been submitted for IND approval in July 2025 [2]. - The company is advancing a 1.1 class innovative drug for treating benign prostatic hyperplasia and related symptoms [2]. Product Development and Clinical Research - The company has achieved significant results in the secondary development of existing products, such as Kun Tai capsules, which have shown efficacy in alleviating perimenopausal syndrome and improving reproductive health [3]. - The company’s product Kushi Gel has been rated as A-level clinical value, demonstrating its effectiveness in maintaining vaginal microecological balance [3]. - The company is conducting a multi-center, randomized, double-blind clinical trial for Ning Mi Tai capsules, approved by the National Medical Products Administration [3]. Investment in Subsidiaries - The company has increased its investment in Huilun Pharmaceutical, recognizing its innovative capabilities and complete commercialization experience [4][5]. - Huilun Pharmaceutical has nearly 20 small molecule drug innovation projects, with over ten expected to enter clinical phases by the end of 2025 [4]. Market Strategy and Challenges - The company’s main products are currently not affected by centralized procurement policies due to their unique patent status [7]. - The company plans to enhance its OTC market presence and brand building to mitigate the impact of market fluctuations [7]. - Rising raw material costs and industry policy changes have led to a temporary decline in revenue, prompting the company to adjust its marketing strategies and strengthen cost control [8][9]. Future Outlook and R&D Focus - The company emphasizes the importance of traditional Chinese medicine (TCM) innovation, aligning with national policy support and market demand for chronic disease treatment [10]. - A balanced approach to short-term and long-term R&D investments is crucial for sustainable growth and shareholder returns [11].